Aulos saw lung tumors shrink up to 48% in early testing. Can its IL-2 combination deliver more?
Aulos Bioscience will present Phase 2 findings for imneskibart, low-dose interleukin-2 and avelumab in checkpoint-resistant lung adenocarcinoma. Earlier findings showed tumor shrinkage in a small cohort, but the forthcoming ESMO data must establish response rates, durability and safety more clearly.